The generic drugmaker Aurobindo Pharma U.S.A. Inc. will not longer be pursuing $200,000 in incentives through the city of Durham. The city was alerted to the agreement termination in a letter from the company on September 6. The city council was told today in an email from city manager Tom Bonfield.
The letter, from Ninad Deshpanday, the North Carolina president of research and development for Aurobindo, says the company still plans to “hire and invest” in Durham, but “some of the compliance requirements related to the agreement are not able to be met by us from a practicality standpoint or are not consistent with our company-wide practices.”
In a September 2 email to Bonfield, the Office of Economic and Workforce Development notified him that Aurobindo was likely to end the agreement because of “included terms of the healthcare coverage for jobs and efforts to inform/include Durham-based firms in the construction efforts.”
